select a format

Single User License
USD 2000 INR 129380
Site License
USD 4000 INR 258760
Corporate User License
USD 6000 INR 388140

Alternatively

Request a quote
Request a Customized research
Request for Sample Report

NEWSLETTER BY CATEGORY




Recent Viewed Reports


Why Ken Reasearch?


Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"


Cervical Cancer-Pipeline Review, H2 2015

Cervical Cancer-Pipeline Review, H2 2015


  • Products Id :- GMDHC7210IDB
  • |
  • Pages: 348
  • |
  • October 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Cervical Cancer-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Cervical Cancer-Pipeline Review, H2 2015', provides an overview of the Cervical Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Cervical Cancer

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Cervical Cancer and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Cervical Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Cervical Cancer pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Cervical Cancer

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Cervical Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Cervical Cancer Overview 10

Therapeutics Development 11

Pipeline Products for Cervical Cancer-Overview 11

Pipeline Products for Cervical Cancer-Comparative Analysis 12

Cervical Cancer-Therapeutics under Development by Companies 13

Cervical Cancer-Therapeutics under Investigation by Universities/Institutes 19

Cervical Cancer-Pipeline Products Glance 20

Late Stage Products 20

Clinical Stage Products 21

Early Stage Products 22

Unknown Stage Products 23

Cervical Cancer-Products under Development by Companies 24

Cervical Cancer-Products under Investigation by Universities/Institutes 29

Cervical Cancer-Companies Involved in Therapeutics Development 30

3SBio Inc. 30

Admedus Ltd 31

Advaxis, Inc. 32

AnGes MG, Inc. 33

Antigen Express, Inc. 34

Arbor Vita Corporation 35

ArQule, Inc. 36

AstraZeneca Plc 37

AVEO Pharmaceuticals, Inc. 38

Azaya Therapeutics, Inc. 39

BIND Therapeutics, Inc. 40

Cancer Research Technology Limited 41

Cellceutix Corporation 42

Chong Kun Dang Pharmaceutical Corp. 43

Critical Outcome Technologies Inc. 44

CZ BioMed Corp 45

Daiichi Sankyo Company, Limited 46

Dr. Reddy's Laboratories Limited 47

EirGenix Inc. 48

Eisai Co., Ltd. 49

Epirus Biopharmaceuticals, Inc. 50

EyeGene, Inc. 51

F. Hoffmann-La Roche Ltd. 52

Formune S.L. 53

Genexine, Inc. 54

Genmab A/S 55

Genor BioPharma Co., Ltd. 56

Genticel S.A. 57

GlaxoSmithKline Plc 58

Hetero Drugs Limited 59

Immunovaccine, Inc. 60

Indian Immunologicals Limited 61

ISA Pharmaceuticals B.V. 62

Karyopharm Therapeutics, Inc. 63

Kite Pharma, Inc. 64

LondonPharma Ltd 65

Mabion SA 66

MedImmune, LLC 67

MEI Pharma, Inc. 68

Mycenax Biotech Inc. 69

Nanotherapeutics, Inc. 70

Nektar Therapeutics 71

Novartis AG 72

Oncobiologics, Inc. 73

Oryx GmbH & Co. KG 74

Otsuka Holdings Co., Ltd. 75

Redbiotec AG 76

Rexahn Pharmaceuticals, Inc. 77

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 78

Shantha Biotechnics Limited 79

Sirnaomics, Inc. 80

Sun Pharma Advanced Research Company Ltd. 81

Taiho Pharmaceutical Co., Ltd. 82

Theravectys SA 83

Vaccibody AS 84

VLPbio 85

Zeria Pharmaceutical Co., Ltd. 86

Zydus Cadila Healthcare Limited 87

Cervical Cancer-Therapeutics Assessment 88

Assessment by Monotherapy Products 88

Assessment by Combination Products 89

Assessment by Target 90

Assessment by Mechanism of Action 94

Assessment by Route of Administration 97

Assessment by Molecule Type 99

Drug Profiles 101

(tegafur + gimeracil + oteracil)-Drug Profile 101

AEH-10p-Drug Profile 105

aminolevulinic acid hydrochloride-Drug Profile 106

Antisense Oligonucleotides for Cervical Cancer-Drug Profile 107

Aptamer to Target HPV E7 Protein for Cervical Cancer-Drug Profile 108

ARQ-092-Drug Profile 109

artemether-Drug Profile 111

AV-203-Drug Profile 113

AVC-7-Drug Profile 114

AZD-1775-Drug Profile 115

AZD-5363-Drug Profile 117

bevacizumab-Drug Profile 119

bevacizumab biosimilar-Drug Profile 125

bevacizumab biosimilar-Drug Profile 126

bevacizumab biosimilar-Drug Profile 127

bevacizumab biosimilar-Drug Profile 128

bevacizumab biosimilar-Drug Profile 129

bevacizumab biosimilar-Drug Profile 130

bevacizumab biosimilar-Drug Profile 131

bevacizumab biosimilar-Drug Profile 132

bevacizumab biosimilar-Drug Profile 133

BLI-1004-Drug Profile 134

buparlisib hydrochloride-Drug Profile 135

Cell Therapy for Cervical Carcinoma-Drug Profile 139

Cell Therapy for HPV Associated Cancers-Drug Profile 140

Cell Therapy for HPV-Associated Cancer and Cervical Cancer-Drug Profile 141

Cell Therapy to Target HPV-16 E6 Protein for Cancer-Drug Profile 143

Cell Therapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer-Drug Profile 145

CerviVax-Drug Profile 146

Cervlysis-Drug Profile 147

CIGB-300-Drug Profile 148

CKD-12201-Drug Profile 150

COTI-2-Drug Profile 151

crocetin-Drug Profile 154

dianhydrogalactitol-Drug Profile 156

docetaxel-Drug Profile 158

docetaxel-Drug Profile 160

DPX-E7-Drug Profile 162

durvalumab + tremelimumab-Drug Profile 163

E-7046-Drug Profile 165

EDA-HPVE7-Drug Profile 166

EG-HPV-Drug Profile 167

etirinotecan pegol-Drug Profile 168

everolimus-Drug Profile 171

GSK-2849330-Drug Profile 177

GX-188E-Drug Profile 178

human papilloma [type 16] vaccine-Drug Profile 179

human papillomavirus vaccine-Drug Profile 180

human papillomavirus vaccine-Drug Profile 181

human papillomavirus vaccine-Drug Profile 182

human papillomavirus vaccine [types 6, 11, 16, 18] biosimilar-Drug Profile 183

HuMax-TF-ADC-Drug Profile 184

INO-3112-Drug Profile 186

ISA-101-Drug Profile 187

KM-3174-Drug Profile 188

Lovaxin S-Drug Profile 192

mapatumumab-Drug Profile 193

ME-344-Drug Profile 195

nimotuzumab-Drug Profile 197

NP-001-Drug Profile 201

NTCP-02-Drug Profile 202

OPB-111001-Drug Profile 203

OTAC-DCtag-Drug Profile 204

paclitaxel albumin free-Drug Profile 206

patritumab-Drug Profile 208

pazopanib hydrochloride-Drug Profile 210

Peptides to Inhibit Bcl-x and MCL-1 for Oncology-Drug Profile 215

ProCervix-Drug Profile 216

RA-190-Drug Profile 218

RBT-201-Drug Profile 219

RX-3117-Drug Profile 220

S-009131-Drug Profile 222

selinexor-Drug Profile 223

Small molecule to Inhibit Bcl-x Protein and MCL-1 for Oncology-Drug Profile 229

SSS-08-Drug Profile 230

STP-909-Drug Profile 231

TA-CIN-Drug Profile 232

TAS-114-Drug Profile 234

Tenacinol-Drug Profile 235

Triapine-Drug Profile 236

TT-12-Drug Profile 238

Vaccine for Cervical Cancer-Drug Profile 239

vaccine for cervical cancer-Drug Profile 240

Vaccine for Cervical Cancer and Genital Warts-Drug Profile 241

Vaccine for Cervical Cancer, Head And Neck Cancer-Drug Profile 242

Vaccine for HPV Associated Cancers-Drug Profile 243

Vaccine for Human papillomavirus Associated Cervical Cancer-Drug Profile 244

Vaccine to Target HIG2, VEGFR-1 and VEGFR-2 for Ovarian Cancer and Cervical Cancer-Drug Profile 245

Vaccine to Target HPV E7 Protein for Cervical Cancer-Drug Profile 246

Vaccine to Target HPV Minor Capsid Protein L2 for Cervical Cancer-Drug Profile 247

VB-1016-Drug Profile 248

Vicoryx-Drug Profile 249

Vvax-001-Drug Profile 250

Z-100-Drug Profile 251

Cervical Cancer-Recent Pipeline Updates 252

Cervical Cancer-Dormant Projects 326

Cervical Cancer-Discontinued Products 331

Cervical Cancer-Product Development Milestones 332

Featured News & Press Releases 332

Appendix 340

Methodology 340

Coverage 340

Secondary Research 340

Primary Research 340

Expert Panel Validation 340

Contact Us 340

Disclaimer 341

List of Tables

Number of Products under Development for Cervical Cancer, H2 2015 18

Number of Products under Development for Cervical Cancer-Comparative Analysis, H2 2015 19

Number of Products under Development by Companies, H2 2015 21

Number of Products under Development by Companies, H2 2015 (Contd...1) 22

Number of Products under Development by Companies, H2 2015 (Contd...2) 23

Number of Products under Development by Companies, H2 2015 (Contd...3) 24

Number of Products under Development by Companies, H2 2015 (Contd...4) 25

Number of Products under Investigation by Universities/Institutes, H2 2015 26

Comparative Analysis by Late Stage Development, H2 2015 27

Comparative Analysis by Clinical Stage Development, H2 2015 28

Comparative Analysis by Early Stage Development, H2 2015 29

Comparative Analysis by Unknown Stage Development, H2 2015 30

Products under Development by Companies, H2 2015 31

Products under Development by Companies, H2 2015 (Contd...1) 32

Products under Development by Companies, H2 2015 (Contd...2) 33

Products under Development by Companies, H2 2015 (Contd...3) 34

Products under Development by Companies, H2 2015 (Contd...4) 35

Products under Investigation by Universities/Institutes, H2 2015 36

Cervical Cancer-Pipeline by 3SBio Inc., H2 2015 37

Cervical Cancer-Pipeline by Admedus Ltd, H2 2015 38

Cervical Cancer-Pipeline by Advaxis, Inc., H2 2015 39

Cervical Cancer-Pipeline by AnGes MG, Inc., H2 2015 40

Cervical Cancer-Pipeline by Antigen Express, Inc., H2 2015 41

Cervical Cancer-Pipeline by Arbor Vita Corporation, H2 2015 42

Cervical Cancer-Pipeline by ArQule, Inc., H2 2015 43

Cervical Cancer-Pipeline by AstraZeneca Plc, H2 2015 44

Cervical Cancer-Pipeline by AVEO Pharmaceuticals, Inc., H2 2015 45

Cervical Cancer-Pipeline by Azaya Therapeutics, Inc., H2 2015 46

Cervical Cancer-Pipeline by BIND Therapeutics, Inc., H2 2015 47

Cervical Cancer-Pipeline by Cancer Research Technology Limited, H2 2015 48

Cervical Cancer-Pipeline by Cellceutix Corporation, H2 2015 49

Cervical Cancer-Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015 50

Cervical Cancer-Pipeline by Critical Outcome Technologies Inc., H2 2015 51

Cervical Cancer-Pipeline by CZ BioMed Corp, H2 2015 52

Cervical Cancer-Pipeline by Daiichi Sankyo Company, Limited, H2 2015 53

Cervical Cancer-Pipeline by Dr. Reddy's Laboratories Limited, H2 2015 54

Cervical Cancer-Pipeline by EirGenix Inc., H2 2015 55

Cervical Cancer-Pipeline by Eisai Co., Ltd., H2 2015 56

Cervical Cancer-Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015 57

Cervical Cancer-Pipeline by EyeGene, Inc., H2 2015 58

Cervical Cancer-Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 59

Cervical Cancer-Pipeline by Formune S.L., H2 2015 60

Cervical Cancer-Pipeline by Genexine, Inc., H2 2015 61

Cervical Cancer-Pipeline by Genmab A/S, H2 2015 62

Cervical Cancer-Pipeline by Genor BioPharma Co., Ltd., H2 2015 63

Cervical Cancer-Pipeline by Genticel S.A., H2 2015 64

Cervical Cancer-Pipeline by GlaxoSmithKline Plc, H2 2015 65

Cervical Cancer-Pipeline by Hetero Drugs Limited, H2 2015 66

Cervical Cancer-Pipeline by Immunovaccine, Inc., H2 2015 67

Cervical Cancer-Pipeline by Indian Immunologicals Limited, H2 2015 68

Cervical Cancer-Pipeline by ISA Pharmaceuticals B.V., H2 2015 69

Cervical Cancer-Pipeline by Karyopharm Therapeutics, Inc., H2 2015 70

Cervical Cancer-Pipeline by Kite Pharma, Inc., H2 2015 71

Cervical Cancer-Pipeline by LondonPharma Ltd, H2 2015 72

Cervical Cancer-Pipeline by Mabion SA, H2 2015 73

Cervical Cancer-Pipeline by MedImmune, LLC, H2 2015 74

Cervical Cancer-Pipeline by MEI Pharma, Inc., H2 2015 75

Cervical Cancer-Pipeline by Mycenax Biotech Inc., H2 2015 76

Cervical Cancer-Pipeline by Nanotherapeutics, Inc., H2 2015 77

Cervical Cancer-Pipeline by Nektar Therapeutics, H2 2015 78

Cervical Cancer-Pipeline by Novartis AG, H2 2015 79

Cervical Cancer-Pipeline by Oncobiologics, Inc., H2 2015 80

Cervical Cancer-Pipeline by Oryx GmbH & Co. KG, H2 2015 81

Cervical Cancer-Pipeline by Otsuka Holdings Co., Ltd., H2 2015 82

Cervical Cancer-Pipeline by Redbiotec AG, H2 2015 83

Cervical Cancer-Pipeline by Rexahn Pharmaceuticals, Inc., H2 2015 84

Cervical Cancer-Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H2 2015 85

Cervical Cancer-Pipeline by Shantha Biotechnics Limited, H2 2015 86

Cervical Cancer-Pipeline by Sirnaomics, Inc., H2 2015 87

Cervical Cancer-Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015 88

Cervical Cancer-Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2015 89

Cervical Cancer-Pipeline by Theravectys SA, H2 2015 90

Cervical Cancer-Pipeline by Vaccibody AS, H2 2015 91

Cervical Cancer-Pipeline by VLPbio, H2 2015 92

Cervical Cancer-Pipeline by Zeria Pharmaceutical Co., Ltd., H2 2015 93

Cervical Cancer-Pipeline by Zydus Cadila Healthcare Limited, H2 2015 94

Assessment by Monotherapy Products, H2 2015 95

Assessment by Combination Products, H2 2015 96

Number of Products by Stage and Target, H2 2015 98

Number of Products by Stage and Mechanism of Action, H2 2015 102

Number of Products by Stage and Route of Administration, H2 2015 105

Number of Products by Stage and Molecule Type, H2 2015 107

Cervical Cancer Therapeutics-Recent Pipeline Updates, H2 2015 259

Cervical Cancer-Dormant Projects, H2 2015 333

Cervical Cancer-Dormant Projects (Contd..1), H2 2015 334

Cervical Cancer-Dormant Projects (Contd..2), H2 2015 335

Cervical Cancer-Dormant Projects (Contd..3), H2 2015 336

Cervical Cancer-Dormant Projects (Contd..4), H2 2015 337

Cervical Cancer-Discontinued Products, H2 2015 338

List of Figures

Number of Products under Development for Cervical Cancer, H2 2015 18

Number of Products under Development for Cervical Cancer-Comparative Analysis, H2 2015 19

Number of Products under Development by Companies, H2 2015 20

Number of Products under Investigation by Universities/Institutes, H2 2015 26

Comparative Analysis by Clinical Stage Development, H2 2015 28

Comparative Analysis by Early Stage Products, H2 2015 29

Assessment by Monotherapy Products, H2 2015 95

Assessment by Combination Products, H2 2015 96

Number of Products by Top 10 Targets, H2 2015 97

Number of Products by Stage and Top 10 Targets, H2 2015 97

Number of Products by Top 10 Mechanism of Actions, H2 2015 101

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 101

Number of Products by Top 10 Routes of Administration, H2 2015 104

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 104

Number of Products by Top 10 Molecule Types, H2 2015 106

Number of Products by Stage and Top 10 Molecule Types, H2 2015 106

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

3SBio Inc.

Admedus Ltd

Advaxis, Inc.

AnGes MG, Inc.

Antigen Express, Inc.

Arbor Vita Corporation

ArQule, Inc.

AstraZeneca Plc

AVEO Pharmaceuticals, Inc.

Azaya Therapeutics, Inc.

BIND Therapeutics, Inc.

Cancer Research Technology Limited

Cellceutix Corporation

Chong Kun Dang Pharmaceutical Corp.

Critical Outcome Technologies Inc.

CZ BioMed Corp

Daiichi Sankyo Company, Limited

Dr. Reddy's Laboratories Limited

EirGenix Inc.

Eisai Co., Ltd.

Epirus Biopharmaceuticals, Inc.

EyeGene, Inc.

F. Hoffmann-La Roche Ltd.

Formune S.L.

Genexine, Inc.

Genmab A/S

Genor BioPharma Co., Ltd.

Genticel S.A.

GlaxoSmithKline Plc

Hetero Drugs Limited

Immunovaccine, Inc.

Indian Immunologicals Limited

ISA Pharmaceuticals B.V.

Karyopharm Therapeutics, Inc.

Kite Pharma, Inc.

LondonPharma Ltd

Mabion SA

MedImmune, LLC

MEI Pharma, Inc.

Mycenax Biotech Inc.

Nanotherapeutics, Inc.

Nektar Therapeutics

Novartis AG

Oncobiologics, Inc.

Oryx GmbH & Co. KG

Otsuka Holdings Co., Ltd.

Redbiotec AG

Rexahn Pharmaceuticals, Inc.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Shantha Biotechnics Limited

Sirnaomics, Inc.

Sun Pharma Advanced Research Company Ltd.

Taiho Pharmaceutical Co., Ltd.

Theravectys SA

Vaccibody AS

VLPbio

Zeria Pharmaceutical Co., Ltd.

Zydus Cadila Healthcare Limited

Cervical Cancer Therapeutic Products under Development, Key Players in Cervical Cancer Therapeutics, Cervical Cancer Pipeline Overview, Cervical Cancer Pipeline, Cervical Cancer Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com